Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects

Status:
Completed

Trial end date:
2013-10-01

Target enrollment:

Participant gender:

The purpose of the study is to evaluate the safety, tolerability, PK and PD of a single-dose of ALXN1007 in healthy volunteers.

Phase 1

Alexion Pharmaceuticals